Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 92Fallopian Tube Neoplasms 25Breast Neoplasms 21Endometrial Neoplasms 19Carcinoma, Ovarian Epithelial 12Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Neoplasms 6Fanconi Anemia, Complementation Group D1 5Uterine Cervical Neoplasms 4Recurrence 4Neoplasm Metastasis 4Carcinoma, Renal Cell 3Uterine Neoplasms 2Stomach Neoplasms 2Peritoneal Neoplasms 2Ovarian Diseases 2Carcinosarcoma 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Relapsed Ovarian Cancers Patients 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Platinum-sensitive Ovarian Cancer 1Platinum-Refractory Fallopian Tube Carcinoma 1

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × olaparib × Gynecologic × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡